Trial Profile
Two Phase, Repeated Crossover Study With Dose Escalation on Delta(9)-Tetrahydrocannabinol (Delta-THC) in Behavioral Disturbances in Dementia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Dronabinol (Primary)
- Indications Alzheimer's disease; Vascular dementia
- Focus Therapeutic Use
- 21 Jan 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 29 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Mar 2012 Additional lead trial centre identified as reported by European Clinical Trials Database record.